438 related articles for article (PubMed ID: 26287518)
1. Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs.
Kim HN; Han L; Iyer S; de Cabo R; Zhao H; O'Brien CA; Manolagas SC; Almeida M
Mol Endocrinol; 2015 Oct; 29(10):1498-509. PubMed ID: 26287518
[TBL] [Abstract][Full Text] [Related]
2. FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC.
Tan P; Guan H; Xie L; Mi B; Fang Z; Li J; Li F
Sci Rep; 2015 Nov; 5():16835. PubMed ID: 26568463
[TBL] [Abstract][Full Text] [Related]
3. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells.
Gurt I; Artsi H; Cohen-Kfir E; Hamdani G; Ben-Shalom G; Feinstein B; El-Haj M; Dresner-Pollak R
PLoS One; 2015; 10(7):e0134391. PubMed ID: 26226624
[TBL] [Abstract][Full Text] [Related]
4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
5. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 suppresses high glucose and palmitate-induced osteoclast differentiation via deacetylating p66Shc.
Qu B; Gong K; Yang H; Li Y; Jiang T; Zeng Z; Cao Z; Pan X
Mol Cell Endocrinol; 2018 Oct; 474():97-104. PubMed ID: 29486220
[TBL] [Abstract][Full Text] [Related]
7. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
8. The Role of FoxOs in Bone Health and Disease.
Kim HN; Iyer S; Ring R; Almeida M
Curr Top Dev Biol; 2018; 127():149-163. PubMed ID: 29433736
[TBL] [Abstract][Full Text] [Related]
9. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress.
Hori YS; Kuno A; Hosoda R; Horio Y
PLoS One; 2013; 8(9):e73875. PubMed ID: 24040102
[TBL] [Abstract][Full Text] [Related]
10. Sirtuin 1 inhibits TNF-α-mediated osteoclastogenesis of bone marrow-derived macrophages through both ROS generation and TRPV1 activation.
Yan S; Miao L; Lu Y; Wang L
Mol Cell Biochem; 2019 May; 455(1-2):135-145. PubMed ID: 30456702
[TBL] [Abstract][Full Text] [Related]
11. Cholesterol sulfate inhibits osteoclast differentiation and survival by regulating the AMPK-Sirt1-NF-κB pathway.
Park JH; Lee J; Lee GR; Kwon M; Lee HI; Kim N; Kim HJ; Lee MO; Jeong W
J Cell Physiol; 2023 Sep; 238(9):2063-2075. PubMed ID: 37334825
[TBL] [Abstract][Full Text] [Related]
12. Suppression of RANKL-dependent heme oxygenase-1 is required for high mobility group box 1 release and osteoclastogenesis.
Sakai E; Shimada-Sugawara M; Nishishita K; Fukuma Y; Naito M; Okamoto K; Nakayama K; Tsukuba T
J Cell Biochem; 2012 Feb; 113(2):486-98. PubMed ID: 21928347
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
14. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
15. Evidence for AKT-independent regulation of FOXO1 and FOXO3 in haematopoietic stem and progenitor cells.
Liang R; Rimmelé P; Bigarella CL; Yalcin S; Ghaffari S
Cell Cycle; 2016; 15(6):861-7. PubMed ID: 26929388
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
17. Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.
Zhou L; Chen X; Yan J; Li M; Liu T; Zhu C; Pan G; Guo Q; Yang H; Pei M; He F
Osteoporos Int; 2017 Dec; 28(12):3325-3337. PubMed ID: 28956094
[TBL] [Abstract][Full Text] [Related]
18. Particle-induced SIRT1 downregulation promotes osteoclastogenesis and osteolysis through ER stress regulation.
Zhang L; Bao D; Li P; Lu Z; Pang L; Chen Z; Guo H; Gao Z; Jin Q
Biomed Pharmacother; 2018 Aug; 104():300-306. PubMed ID: 29775898
[TBL] [Abstract][Full Text] [Related]
19. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
